As President and CEO of Zomedica, Gerald Solensky is determined to revolutionize the animal health industry by building an unprecedented business model alongside a world-class leadership team. An industry trailblazer known for his goals-driven leadership style, astute business acumen, and leading-edge people strategies, Gerald is committed to helping animals by ensuring the success of the veterinarians who care for them.
With a 20-year track-record building successful operations within start-up, turnaround and rapid-change environments, Gerald started his career with Yamaha Motors as the youngest executive to command national and international accounts averaging $50 million in total sales. He subsequently entered the banking industry serving as Regional Vice President of Fifth Third Bank where he managed a $250 million portfolio. He further expanded his financial and leadership talents as Senior Vice President at IndyMac Bank where he managed the P&L statement and 120 sales professionals in the mortgage-backed security division. Prior to joining Zomedica, Gerald served as Director, President and CEO at Dynamic Fuel Systems (now dynaCERT Inc.), a TSX-V listed fuel system technology firm. Most recently, Gerald authored a consumer financial education program titled “Life 101” and completed over 800 observation hours in pre-veterinary medicine to garner a more complete understanding of Zomedica’s veterinary customer and their associated needs.
Outside his charge with Zomedica, Gerald is an avid collector of deep cameo coins as well as keepsakes that mark special memories of his family life. His constant animal companion is a Jack Russell terrier named Capone, and his home has served as rehabilitation haven to many creatures including a hummingbird, two raccoons, a rabbit, and countless ducks, squirrels, chipmunks, and birds.
William C. MacArthur, MS, DVM, is Zomedica’s Chief Medical Officer and Director of R&D and serves on the company’s Board of Directors. A scientific trailblazer, he leverages his first-hand understanding of clinical veterinary practice to quickly develop the right mix of products to solve the daily, real-world problems of veterinarians. He and his team are focused on helping veterinarians lower costs, increase revenues, provide education, and greet clinical and business challenges with confidence.
Dr. MacArthur brings a breadth and depth of clinical knowledge and animal biotechnology expertise to his role. He founded GeneWorks, a small cap biotechnology startup based on his discovery of a method for expressing large quantities of human protein into the egg whites of transgenic hens. He served as CEO and Institutional Veterinarian for the firm, which established a post-money valuation of $35 million. In addition, he previously owned and operated a six-doctor small animal clinical practice, where he particularly enjoyed solving difficult diagnosis challenges. Dr. MacArthur earned Bachelor of Science degrees in zoology, biochemistry, and chemistry from the University of Massachusetts Amherst, a Master of Science in cellular and molecular biology from the University of Michigan, and doctor of veterinary medicine from Michigan State University.
Outside of his professional pursuits, Dr. MacArthur is an inventor and tinkerer. He is co-creator of Insectazoids, a battling robot toy that was named runner up “Toy of the Year” for boys aged 8-13 years by Family Fun Magazine. He also enjoys clock-making and spending time with his family, which wouldn’t be complete without an American fox hound named McCoy, two cats named Dr. Jekyll and Mr. Hyde, a ball python, an albino corn snake, and two Russian tortoises.
As the Chief Operations Officer of Zomedica, Stephanie L. Morley, DVM, is charged with developing the core business structure and aligning daily operations in support of the company’s business model to effectively serve its vision and mission. To do this, she is focused on creating competitive advantage by building lean business operations that improve efficiency, agility and scalability by constantly mapping efforts to strategic goals and objectives. This approach is imperative to growing Zomedica into a credible business that both veterinarians and investors believe in and value.
Dr. Morley is a trained veterinarian with instinctive business acumen. Over the course of her 15 year career, she has become known as a transformational leader, experienced in building viable business units and overseeing departments with 600 plus staff and annual budgets totaling US$40 million in operating expenses. After earning a Bachelor of Arts in hospitality business and doctor of veterinary medicine from Michigan State University, Dr. Morley was a practicing veterinarian with Oakwood Animal Hospital in Kalamazoo, MI and Adobe Animal Medical Center in Albuquerque, NM where she quickly learned to juggle the roles of both clinical practitioner and operations management. During her tenure with MPI Research, she was rapidly promoted to increasingly responsible positions, advancing from lower-level supervisory roles to Vice President of Operations by building rapport with divisions and departments to instill a cohesive team atmosphere. As Associate Director of Business Development with the University of Michigan Medical School, Dr. Morley bridged communications between faculty members and external industry, translating science to business and business to science, in efforts to fast track innovations from discovery insight to market impact.
When she is not building the business, Dr. Morley can be found downhill skiing or tackling home improvement projects alongside her husband and their five children. Her personal tenet is to have fun in all endeavors and be the best example possible to her family, friends, community and professional network that are part of her journey.
As Chief Financial Officer and Corporate Secretary of Zomedica’s Canadian-based parent company, Shameze Rampertab, CPA, CA, is focused on strengthening the company’s capital structure via the development and implementation of financial strategies to ensure continued growth and viability in the evolving animal health market. Based in Canada, his ongoing responsibilities include financial reporting and guidance, treasury and foreign exchange management, tax planning, fundraising and investor relations.
A seasoned financial leader in the healthcare sector with 20 years of experience, Shameze is a master of capital markets, strategic planning and financial analysis. Over the course of his distinctive and accomplished career, he successfully served as chief financial officer for multiple publicly traded healthcare startups, worked as an investment banker, thrived as a sell-side health-equity research analyst, and raised over $480 million of private and public capital. Before joining Zomedica, Shameze served as CFO and secretary at Profound Medical Corp. where he spearheaded a Qualifying Transaction with a Capital Pool Corporation resulting in the listing of shares on the TSX Venture Exchange. Prior to that, he was CFO and Vice President of Finance for Intellipharmaceutics International Inc., a NADSAQ and TSX listed pharmaceutical company. He received his chartered professional accountant (CPA) and chartered accountant (CA) designations from the Canadian Institute of Chartered Accountants after earning his MBA from McMaster University and Bachelor of Science in molecular genetics and molecular biology from the University of Toronto.
A kid at heart, Shameze is an avid marathon runner, motorcycle rider, and volunteer judge for FIRST® LEGO® League competitions, with the latter inspired by his children’s positive and impactful experiences with this STEM-focused educational organization. He shares his home with Gizmo, an orange tabby, and Bruce, a Yorkshire Terrier, who all live in harmony with his wife and three children.
As the Executive Vice President of Global Strategy of Zomedica, Robert DiMarzo is responsible for evolving Zomedica’s business beyond North America via globalization strategies for existing and future product pipelines as well as fostering business development opportunities.
Robert is a dynamic executive with an affinity for relationship building and cultivating opportunities for new products and technologies. Robert began his career with Elanco, the animal health division of Eli Lilly, followed by 15 years with Pfizer Animal Health (now Zoetis). During his tenure, Robert served in various commercial capacities and geographies including both Brazil and Italy. In his last position he elevated Pfizer’s U.S. Animal Health division to that of a recognized industry leader. After completing his work with Pfizer, Robert was the Executive Vice President of Sales and Marketing for the veterinary diagnostic startup Scandinavian Micro Biodevices (SMB), which was purchased by Zoetis in 2016. Following his time at SMB, he was Executive Chairman of the U.S. animal health distributor IVESCO Holdings LLC. Under his leadership, IVESCO transformed into a successful category leader that was acquired in November 2013 by MWI Veterinary Supply, Inc. Robert also had a stint as Vice President of Commercial Development and Product Category Management with the global animal health group at Henry Schein. Prior to joining the Zomedica team, Robert was Principal with DiMarzo Business Consulting where he advised business, financial, and government entities on globalization, business development, and growth strategies within the animal health and human biotechnology industries.
Before his work in the animal health industry, Robert served as a U.S. Naval Officer and Peace Corps volunteer. Robert holds a Master of Business Administration from Harvard University and Bachelor of Science from Brown University.
Outside of the office, Robert has a fondness for travel and different cultures as well as the beach and oceans. When he isn’t trotting across the globe, he’s an avid sportsman and fan of cycling, American football, soccer and lacrosse. Robert also enjoys spending time with his wife and kids. He also frequently finds ways to honor and give back to members of our military.
Complete the form below to receive automated email alerts on the latest news from Zomedica.
Copyright © 2016 - 2017 Zomedica Pharmaceuticals Corp. and Zomedica Pharmaceuticals Inc. All Rights Reserved.